As its slide stretches into a second year, Zymeworks faces takeover bid

As its slide stretches into a second year, Zymeworks faces takeover bid

Source: 
Endpoints
snippet: 

Zymeworks’ new CEO Kenneth Galbraith has vastly remade the nearly 20-year-old biotech in the few short months he’s run the show. But his efforts to turn things around have apparently ruffled some feathers.